In vivo studies showed that miR-146a loss in mouse hematopoietic stem and progenitor cells (HSPC) promoted MDS/AML by increasing TRAF6 expression and NF-κB activation [54,55,56]. Here, TRAF6 is linked to acute myeloid leukemia.